ArticleClinical drug investigation2025

Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study.

Michael Gerometta et al.PubMed ↗Publisher ↗

No numbers read from the abstract.